This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DOD beneficiaries treated at military medical treatment facilities.

Upon transfer, the Director, DHA, will assume responsibility for ensuring all Armed Services Blood Program (ASBP) activities are FDA-compliant.

This PGI provides standard language that shall be included in all purchased and non-purchased care solicitations and contracts where the contractor’s performance involves access to PII/PHI (unless those solicitations and contracts incorporate the TRICARE Manuals in their entirety, in which case this PGI does not apply).

In accordance with the authority in DOD Directive 5124.02, this issuance establishes policy, assigns responsibilities, and prescribes procedures regarding the standards for military service accession, retention, separation, in-service transition, and medical care for Service members and applicants for accession to the Military Services with gender ...

The Department of Defense (DOD) Pharmacy and Therapeutics (P&T) Committee (henceforth, P&T Committee) is responsible for development and maintenance of the TRICARE Uniform Formulary. This charter outlines the roles and responsibilities of the DOD P&T Committee.

This memorandum contains the DOD UBO Revised Calendar Year 2019 Outpatient Medical, Dental, and Elective Cosmetic Procedure Reimbursement Rates and Guidance.

This memorandum contains the DOD Calendar Year 2020 Outpatient Medical, Dental, and Elective Cosmetic Procedure Reimbursement Rates and Guidance

This Memorandum of Understanding rescinds and replaces the Supplement to the Department of Veterans Affairs and the Department of Defense Health Care Resources Sharing Guidelines, dated Dec. 5, 2016. VA and DOD are collectively referred to in the MOU as “Partners”.